GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.
A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic.
The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.
Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.
Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.
In Science this week: gut microbiome influences liver cancer growth, spread; and more.